Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OptimizeRx Corporation - Common Stock (NQ:OPRX)

8.250 -0.200 (-2.37%)
Streaming Delayed Price Updated: 1:56 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OptimizeRx Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment
From OptimizeRx Corporation
Via GlobeNewswire
Unusual volume stocks in Thursday's session
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Top movers in Wednesday's session
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
Where OptimizeRx Stands With Analysts
Via Benzinga
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: OptimizeRx's Earnings
Via Benzinga
Which stocks are experiencing notable movement on Wednesday?
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
A Closer Look at 5 Analyst Recommendations For OptimizeRx
Via Benzinga
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
OptimizeRx reports sales of $32.32M in Q4, beating consensus, with adjusted EPS of $0.30. Full-year revenue increased 29% and EBITDA grew 53%. 
Via Benzinga
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
No Stockholder Action Required at this Time 
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team 
From OptimizeRx Corporation
Via GlobeNewswire
Earnings Scheduled For March 12, 2025
Via Benzinga
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
OptimizeRx Reports Third Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
From OptimizeRx Corporation
Via GlobeNewswire
OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024
OPRX stock results show that OptimizeRx beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
OptimizeRx Reports Second Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide 
From OptimizeRx Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.